GLP-1 receptor agonists (GLP-1 RAs) are approved for the treatment of type 2 diabetes and obesity and have gained widespread use due to their effectiveness in reducing both A1c levels and body weight. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.